Feature | January 03, 2013

FDA Approves Abbott’s Next-Generation Xience Xpedition Drug-Eluting Stent

New stent offers enhanced deliverability, largest size matrix in U.S. market

abbott Xience Xpedition stent

January 3, 2013 — Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market. Xience Xpedition features a new stent delivery system designed to optimize deliverability, particularly in challenging coronary anatomies.

Samin K. Sharma, M.D., director of clinical and interventional cardiology, dean of international clinical affiliations, and president of the Mount Sinai Heart Network at Mount Sinai Medical Center, New York, was the first physician to implant a patient with Xience Xpedition in the United States.

"Xience Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes, three factors that make this product well-suited to treat a wide range of patients," Sharma said. "The impact of the changes to the stent delivery system is particularly notable in patients with complex coronary anatomy. For these patients, physicians have a new technology to reach the blockage and restore blood flow with ease and confidence."

Abbott's Xience drug-eluting stents, including the newly approved Xience Xpedition, are the first and only drug-eluting stents in the U.S. market to be proven safe for direct stenting. Direct stenting, a technique in which the stent system is not preceded by another device (such as a balloon dilatation catheter) to prepare the lesion, has the potential to save time and resources in the catheterization laboratory. Xience Xpedition is supported by rclinical evidence from the Xience family of drug-eluting stents, including data from more than 45,000 patients across more than 100 studies, with long-term outcomes out to five years. Data have consistently shown an excellent safety profile for the Xience family of stents.

"The launch of Xience Xpedition in the United States will advance Abbott's worldwide market-leading position in drug-eluting stents," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Xience Xpedition leverages the strong clinical outcomes of Xience V and Xience Prime while providing important advantages in deliverability. With its redesigned stent delivery system and a full matrix of sizes, Xience Xpedition provides physicians with a comprehensive, trusted option to treat a broad range of patients with coronary artery disease."

Xience Xpedition will be available in the largest size matrix in the U.S. market, with both rapid exchange (RX) and over-the-wire (OTW) configurations, providing physicians with the most popular delivery platforms. The stent has diameters ranging from 2.25 mm to 4 mm, including a unique 3.25 mm diameter, and lengths from 8 mm to 38 mm, for more accurate vessel sizing.

For more information: www.abbott.com

Related Content

smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Robert M. Califf, FDA commissioner, future of cardiovascular medicine, JACC column
News | Business| September 23, 2016
Technology advances coupled with increased use of social media and personal devices could offer new possibilities for...
Medtronic, In.Pact Admiral drug-coated balloon, trial data, VIVA
News | Drug-Eluting Balloons| September 22, 2016
New data presented at the Vascular Interventional Advances (VIVA) conference demonstrated the durability, consistency...
4Tech, TriCinch TTVR, transcather tricuspid valve repair device, first implant
News | Heart Valve Technology| September 22, 2016
4Tech Inc. announced that its TriCinch device has been used in the world’s first-ever successful transcatheter...
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
Sponsored Content | Videos | Inventory Management| September 21, 2016
With bundled payments putting increased pressure on hospitals to manage supply costs while providing quality patient
Claret Medical, Sentinal CPS, cerebral protection system, FDA marketing application, TAVR, embolic protection
News | Embolic Protection Devices| September 20, 2016
Claret Medical announced its filing of a marketing application with the U.S. Food and Drug Administration (FDA) for...
Teleflex, AVA 2016 Congress, Association for Vascular Access
News | Vascular Access| September 20, 2016
September 20, 2016 — Teleflex Inc.
Edwards sapien, intermediate risk patients, CE mark
News | Heart Valve Technology| September 20, 2016
September 19, 2016 — Edwards Lifesciences received European CE mark to expand use of the Edwards Sapien 3 transcathet
Shockwave medical, lithoplasty
News | Cath Lab| September 19, 2016
September 19, 2016 — Shockwave Medical announced positive clinical results from the pooled DISRUPT PAD Study, a singl
Overlay Init